ABX Acquires TRIMT GmbH to Accelerate the Next Generation of Integrin-Targeted Theranostics
Acquisition adds a proprietary cyclopeptide platform and investigational αvβ6- and αvβ8-integrin targeted diagnostic and therapeutic radiopharmaceuticals to ABX’s precision-oncology pipeline
Radeberg, 7th of September 2026. ABX today announced the acquisition of TRIMT GmbH, a biotechnology company developing radiopharmaceuticals targeting the integrins αvβ6 and αvβ8. The acquisition expands ABX’s precision-oncology pipeline with a proprietary integrin targeted radiopharmaceutical platform and brings together TRIMT’s scientific innovation in cyclopeptide ligands with ABX’s end-to-end capabilities in radiopharmaceutical development, clinical manufacturing, regulatory support, commercialization and global supply.
TRIMT has a proprietary portfolio of cyclopeptide-based compounds, including the αvβ6-integrin targeted PET imaging agent ⁶⁸Ga-Trivehexin and the therapeutic candidate ¹⁷⁷Lu-Therahexin, as well as the αvβ8-integrin targeted PET imaging agent ⁶⁸Ga-Triveoctin. All three compounds are investigational and have not been approved for commercial use.
The integrins αvβ6 and αvβ8 are cell-surface receptors that are expressed at low levels in many healthy adult tissues but can be upregulated in cancer and other diseases. This makes them attractive targets for molecular imaging and targeted radionuclide therapy.
Clinical and translational research has demonstrated the potential to visualize integrin expression across a range of epithelial malignancies. ⁶⁸Ga-Trivehexin, ¹⁷⁷Lu-Therahexin, and⁶⁸Ga-Triveoctin are currently under clinical investigation, and their safety and efficacy have not been established.
The acquisition provides ABX with the rights to develop and commercialize TRIMT's proprietary intellectual property, cyclopeptide technology platform, and clinical-stage development portfolio, creating the opportunity to further advance both diagnostic and therapeutic applications within the rapidly growing theranostics landscape.
“The acquisition of TRIMT and its integrin-targeted platform marks an important step in the expansion of ABX’s oncology portfolio,” said Dr. Marco Müller, CEO of ABX. “Trivehexin, Therahexin and Triveoctin provide us with an exciting scientific and clinical foundation. By combining TRIMT’s expertise in integrin biology with ABX’s clinical development, manufacturing and global supply capabilities, we aim to advance these programs efficiently and responsibly. We aim to create new options for patients with cancers that remain difficult to diagnose and treat.”
ABX will build on its 30 years of experience across the radiopharmaceutical value chain - from early research and development to clinical manufacturing, regulatory support, commercialization and worldwide supply - to support ongoing and future clinical programs for the acquired portfolio. ABX’s track record includes contributing to the development of the prostate cancer therapeutic ¹⁷⁷Lu-PSMA-617 through Phase II before sublicensing the program to Endocyte, now part of Novartis. The company also developed the prostate cancer imaging agent ¹⁸F-PSMA-1007, which is approved in selected countries across Europe, Asia and North Africa.
“When we founded TRIMT, our vision was to translate an outstanding class of integrin binding molecules biology into radiopharmaceuticals that could make a meaningful difference for cancer patients,” said TRIMT founders Dr. Jakub Simecek, Dr. Johannes Notni and Dr. Dirk Freitag-Stechl in a joint statement. “Together with our exceptional scientific team, we have developed this vision into a leading integrin-targeting platform. In ABX, we have found the right partner to advance its clinical development and work toward bringing these innovations to patients worldwide.”
The acquisition reinforces ABX’s commitment to precision oncology, molecular imaging, and targeted radionuclide therapy while establishing a strong foundation for the next generatio nof integrin-targeted radiopharmaceuticals.
About ABX GmbH
ABX is a fully owned subsidiary of CIL (Cambridge Isotope Laboratories, Inc., USA), which is itself a 100% owned subsidiary of Otsuka Pharmaceutical Co., Ltd., a global healthcare company headquartered in Japan. As a trusted partner in radiopharmaceutical innovation, ABX provides expertise across the full value chain - from early research and development to clinical manufacturing, regulatory support, commercialization and global supply. ABX’s portfolio combines radiopharmaceutical products with CMO and CDMO services. With 30years of experience, GMP-compliant manufacturing and global supply capabilities, ABX helps customers manage complex radiopharmaceutical programs through one experienced partner. Trusted Excellence defines how ABX works - from molecule to market, advancing nuclear medicine and improving patient care worldwide.
About TRIMT GmbH
Founded in Radeberg, Saxony, in 2021, TRIMT GmbH is a biotechnology company focused on the development of proprietary integrin-targeted radiopharmaceuticals. Its cyclopeptide platform includes the clinical-stage αvβ6-targeted compounds ⁶⁸Ga-Trivehexin and ¹⁷⁷Lu-Therahexin, as well as the αvβ8-targeted PET imaging agent ⁶⁸Ga-Triveoctin for oncology applications. All three compounds are investigational and have not been approved for commercial use. Their safety and efficacy have not been established. ABX aims to advance these programs efficiently and responsibly, with the goal of potentially creating new options for patients with cancers that remain difficult to diagnose and treat.
Press Contact:
ir@abx.de
www.abx.de
Press release
TRIMT has a proprietary portfolio of cyclopeptide-based compounds, including the αvβ6-integrin targeted PET imaging agent ⁶⁸Ga-Trivehexin and the therapeutic candidate ¹⁷⁷Lu-Therahexin, as well as the αvβ8-integrin targeted PET imaging agent ⁶⁸Ga-Triveoctin. All three compounds are investigational and have not been approved for commercial use.
The integrins αvβ6 and αvβ8 are cell-surface receptors that are expressed at low levels in many healthy adult tissues but can be upregulated in cancer and other diseases. This makes them attractive targets for molecular imaging and targeted radionuclide therapy.
Clinical and translational research has demonstrated the potential to visualize integrin expression across a range of epithelial malignancies. ⁶⁸Ga-Trivehexin, ¹⁷⁷Lu-Therahexin, and⁶⁸Ga-Triveoctin are currently under clinical investigation, and their safety and efficacy have not been established.
The acquisition provides ABX with the rights to develop and commercialize TRIMT's proprietary intellectual property, cyclopeptide technology platform, and clinical-stage development portfolio, creating the opportunity to further advance both diagnostic and therapeutic applications within the rapidly growing theranostics landscape.
“The acquisition of TRIMT and its integrin-targeted platform marks an important step in the expansion of ABX’s oncology portfolio,” said Dr. Marco Müller, CEO of ABX. “Trivehexin, Therahexin and Triveoctin provide us with an exciting scientific and clinical foundation. By combining TRIMT’s expertise in integrin biology with ABX’s clinical development, manufacturing and global supply capabilities, we aim to advance these programs efficiently and responsibly. We aim to create new options for patients with cancers that remain difficult to diagnose and treat.”
ABX will build on its 30 years of experience across the radiopharmaceutical value chain - from early research and development to clinical manufacturing, regulatory support, commercialization and worldwide supply - to support ongoing and future clinical programs for the acquired portfolio. ABX’s track record includes contributing to the development of the prostate cancer therapeutic ¹⁷⁷Lu-PSMA-617 through Phase II before sublicensing the program to Endocyte, now part of Novartis. The company also developed the prostate cancer imaging agent ¹⁸F-PSMA-1007, which is approved in selected countries across Europe, Asia and North Africa.
“When we founded TRIMT, our vision was to translate an outstanding class of integrin binding molecules biology into radiopharmaceuticals that could make a meaningful difference for cancer patients,” said TRIMT founders Dr. Jakub Simecek, Dr. Johannes Notni and Dr. Dirk Freitag-Stechl in a joint statement. “Together with our exceptional scientific team, we have developed this vision into a leading integrin-targeting platform. In ABX, we have found the right partner to advance its clinical development and work toward bringing these innovations to patients worldwide.”
The acquisition reinforces ABX’s commitment to precision oncology, molecular imaging, and targeted radionuclide therapy while establishing a strong foundation for the next generatio nof integrin-targeted radiopharmaceuticals.
About ABX GmbH
ABX is a fully owned subsidiary of CIL (Cambridge Isotope Laboratories, Inc., USA), which is itself a 100% owned subsidiary of Otsuka Pharmaceutical Co., Ltd., a global healthcare company headquartered in Japan. As a trusted partner in radiopharmaceutical innovation, ABX provides expertise across the full value chain - from early research and development to clinical manufacturing, regulatory support, commercialization and global supply. ABX’s portfolio combines radiopharmaceutical products with CMO and CDMO services. With 30years of experience, GMP-compliant manufacturing and global supply capabilities, ABX helps customers manage complex radiopharmaceutical programs through one experienced partner. Trusted Excellence defines how ABX works - from molecule to market, advancing nuclear medicine and improving patient care worldwide.
About TRIMT GmbH
Founded in Radeberg, Saxony, in 2021, TRIMT GmbH is a biotechnology company focused on the development of proprietary integrin-targeted radiopharmaceuticals. Its cyclopeptide platform includes the clinical-stage αvβ6-targeted compounds ⁶⁸Ga-Trivehexin and ¹⁷⁷Lu-Therahexin, as well as the αvβ8-targeted PET imaging agent ⁶⁸Ga-Triveoctin for oncology applications. All three compounds are investigational and have not been approved for commercial use. Their safety and efficacy have not been established. ABX aims to advance these programs efficiently and responsibly, with the goal of potentially creating new options for patients with cancers that remain difficult to diagnose and treat.
Press Contact:
ir@abx.de
www.abx.de
Press release